On June 1, more than 25,000 cancer specialists will come together at the 2012 American Society of Clinical Oncology Annual Meeting in Chicago. With ASCO hours away, we look at some small biotech companies making headway in cancer treatment.
Biovest has developed a patient-specific, cancer vaccine, BiovaxID®, with three clinical trials completed.
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for antiviral therapy.
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
In this special series we present emerging technologies which hold the promise to significantly improve the prognosis of patients diagnosed with prostate cancer, and cancer in general.
Author of “The Creative Destruction of Medicine: How the Digital Revolution Will Create Better Healthcare”, Dr. Eric Topol sits down with OneMedRadio to discuss the ideas and inspiration behind the book.
The New York Biotech Association Annual Meeting last Wednesday and Thursday was a success, showcasing 15 emerging companies as well as two dozen panels over the two-day span. Held in the Marriott Marquis Hotel, a staple of Times Square, the 21st annual conference was well attended.
Part II of the report identifies several disruptive technologies that may overcome the challenges of mainstream treatments.